Lead Product(s) : Bromelain
Therapeutic Area : Trauma (Emergency, Injury, Surgery)
Study Phase : Phase II
Sponsor : H.C. Wainwright & Co
Deal Size : $27.5 million
Deal Type : Public Offering
MediWound Announces Closing of $27.5 Million Registered Direct Offering of Ordinary Shares
Details : The Company intends to use the net proceeds from the offering primarily for the acceleration of the development of EscharEx® (bromelain), establishing a U.S. commercial presence, supporting business development activities, and for general corporate purp...
Product Name : NexoBrid
Product Type : Enzyme
Upfront Cash : Undisclosed
July 02, 2023
Lead Product(s) : Bromelain
Therapeutic Area : Trauma (Emergency, Injury, Surgery)
Highest Development Status : Phase II
Sponsor : H.C. Wainwright & Co
Deal Size : $27.5 million
Deal Type : Public Offering
Lead Product(s) : Bromelain
Therapeutic Area : Trauma (Emergency, Injury, Surgery)
Study Phase : Phase II
Sponsor : H.C. Wainwright & Co
Deal Size : $27.5 million
Deal Type : Public Offering
MediWound Announces $27.5 Million Registered Direct Offering of Ordinary Shares Priced At-The-Market
Details : The Company intends to use the net proceeds from the offering primarily for the acceleration of the development of EscharEx. EscharEx, a concentrate of proteolytic enzymes enriched in bromelain, is an easy to use product candidate, for topical daily appl...
Product Name : NexoBrid
Product Type : Enzyme
Upfront Cash : Undisclosed
March 02, 2023
Lead Product(s) : Bromelain
Therapeutic Area : Trauma (Emergency, Injury, Surgery)
Highest Development Status : Phase II
Sponsor : H.C. Wainwright & Co
Deal Size : $27.5 million
Deal Type : Public Offering
Lead Product(s) : Bromelain Enriched Proteolytic Enzyme
Therapeutic Area : Trauma (Emergency, Injury, Surgery)
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Study met primary endpoint with patients treated with EscharEx (Bromelain Enriched Proteolytic Enzyme) had statistically significant higher incidence of complete debridement during the 14-day measurement period within up to 8 applications compared to gel...
Product Name : EscharEx
Product Type : Enzyme
Upfront Cash : Inapplicable
December 05, 2022
Lead Product(s) : Bromelain Enriched Proteolytic Enzyme
Therapeutic Area : Trauma (Emergency, Injury, Surgery)
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Bromelain Enriched Proteolytic Enzyme
Therapeutic Area : Trauma (Emergency, Injury, Surgery)
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : EscharEx, a concentrate of proteolytic enzymes enriched in bromelain, for debridement of chronic and other hard-to-heal wounds is a product candidate in advanced stages of development.
Product Name : EscharEx
Product Type : Enzyme
Upfront Cash : Inapplicable
December 04, 2022
Lead Product(s) : Bromelain Enriched Proteolytic Enzyme
Therapeutic Area : Trauma (Emergency, Injury, Surgery)
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Bromelain Enriched Proteolytic Enzyme
Therapeutic Area : Trauma (Emergency, Injury, Surgery)
Study Phase : Phase II
Sponsor : H.C. Wainwright & Co
Deal Size : $30.0 million
Deal Type : Private Placement
Details : The Company intends to use the net proceeds from the Offerings primarily for the development of EscharEx® (bromelain enriched proteolytic enzyme), a scale up of its facilities, and for general corporate purposes.
Product Name : EscharEx
Product Type : Enzyme
Upfront Cash : Undisclosed
September 22, 2022
Lead Product(s) : Bromelain Enriched Proteolytic Enzyme
Therapeutic Area : Trauma (Emergency, Injury, Surgery)
Highest Development Status : Phase II
Sponsor : H.C. Wainwright & Co
Deal Size : $30.0 million
Deal Type : Private Placement
Lead Product(s) : Bromelain Enriched Proteolytic Enzyme
Therapeutic Area : Trauma (Emergency, Injury, Surgery)
Study Phase : Phase II
Sponsor : H.C. Wainwright & Co
Deal Size : $30.5 million
Deal Type : Public Offering
MediWound Announces Closing of the Concurrent Registered Direct and Private Placement Offerings
Details : The Company intends to use the net proceeds for the development of EscharEx® (bromelain enriched proteolytic enzyme), which has demonstrated safety and efficacy in the debridement of various chronic and other hard-to-heal wounds and scale up of its faci...
Product Name : EscharEx
Product Type : Enzyme
Upfront Cash : Undisclosed
July 10, 2022
Lead Product(s) : Bromelain Enriched Proteolytic Enzyme
Therapeutic Area : Trauma (Emergency, Injury, Surgery)
Highest Development Status : Phase II
Sponsor : H.C. Wainwright & Co
Deal Size : $30.5 million
Deal Type : Public Offering
Lead Product(s) : Bromelain Enriched Proteolytic Enzyme
Therapeutic Area : Trauma (Emergency, Injury, Surgery)
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Preliminary efficacy and safety data from study in patients with venous leg ulcers and diabetic foot ulcers, from a clinical pharmacology study demonstrating EscharEx's fast and effective debriding activity accompanied with reduction in biofilm and bacte...
Product Name : EscharEx
Product Type : Enzyme
Upfront Cash : Inapplicable
March 29, 2022
Lead Product(s) : Bromelain Enriched Proteolytic Enzyme
Therapeutic Area : Trauma (Emergency, Injury, Surgery)
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Bromelain Enriched Proteolytic Enzyme
Therapeutic Area : Trauma (Emergency, Injury, Surgery)
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Patients treated with EscharEx (proteolytic enzymes enriched in bromelain), demonstrated a higher incidence of complete debridement during the 14-day measurement period within up to 8 applications compared to patients treated with gel vehicle.
Product Name : EscharEx
Product Type : Enzyme
Upfront Cash : Inapplicable
March 21, 2022
Lead Product(s) : Bromelain Enriched Proteolytic Enzyme
Therapeutic Area : Trauma (Emergency, Injury, Surgery)
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Bromelain Enriched Proteolytic Enzyme
Therapeutic Area : Trauma (Emergency, Injury, Surgery)
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : The study concluded that EscharEx treatment was more effective than the commercially available collagenase agent in removing eschars in this model.
Product Name : EscharEx
Product Type : Enzyme
Upfront Cash : Inapplicable
December 21, 2020
Lead Product(s) : Bromelain Enriched Proteolytic Enzyme
Therapeutic Area : Trauma (Emergency, Injury, Surgery)
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable